Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 10/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | OXTR | P30559 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12034937 | 1.00 | HPGD (0.42) | HPGDNAMPTF2ALDH1A1MAPK1 | |
| SCHEMBL1306682 | 0.93 | HPGD (0.44) | HPGDNAMPTF2ALDH1A1MAPK1 | |
| SCHEMBL1307339 | 0.90 | HPGD (0.47) | HPGDNAMPTF2ALDH1A1MAPK1 | |
| SCHEMBL1306300 | 0.89 | MAPK1 (0.48) | HPGDALDH1A1MAPK1OXTRTSHR | |
| SCHEMBL1306667 | 0.88 | HPGD (0.42) | HPGDNAMPTF2ALDH1A1MAPK1 | |
| SCHEMBL3812592 | 0.81 | HSD17B10 (0.46) | HPGDNAMPTF2ALDH1A1MAPK1 | |
| SCHEMBL1307674 | 0.81 | HPGD (0.43) | HPGDNAMPTALDH1A1MAPK1MEN1 | |
| SCHEMBL12117301 | 0.80 | HPGD (0.45) | HPGDNAMPTALDH1A1MAPK1OXTR | |
| SCHEMBL1308010 | 0.79 | HPGD (0.46) | HPGDNAMPTF2ALDH1A1OXTR | |
| SCHEMBL1307673 | 0.78 | HPGD (0.41) | HPGDNAMPTF2ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118259-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-07 | — | — | US | claimed |
| EP-1945207-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | Transtech Pharma, Inc. (US) | 2008-07-23 | — | — | EP | claimed |
| WO-2007051811-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | TRANSTECH PHARMA (US) | 2007-05-10 | — | — | WO | claimed |
| US-20110312949-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-12-22 | — | — | US | disclosed |
| US-8053431-B2 | Pharmaceutical use of substituted amides | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-20090118259-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-07 | — | — | US | disclosed |
| EP-1945207-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | Transtech Pharma, Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007051811-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | TRANSTECH PHARMA (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118259-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HSD11B1, CYP11B1, HSD11B2 | HPGD 27/4885NAMPT 1378/4885F2 3595/4885 |
| US-20110312949-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HSD11B1, HSD3B1, HSD11B2 | HPGD 28/4885NAMPT 1483/4885F2 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.